GRID EXPONENTIAL
VC Fund
Buenos Aires, Argentina
GRID EXPONENTIAL is a VC fund in Buenos Aires focused on Biotechnology and Life Science. We are aware about the complexity of the technology transfer and investment process in LATAM, resulting in a very low existence and creation of sucesful science based companies.We focus on creating a bridge, a new technology transfer process that will lead to the creation of high impact, global, disruptive and sustainable companies that willchange the world.WE ARE THE FIRST SCIENCE BASED COMPANY BUILDER IN LATIN AMERICA
- Total investments:
- 102
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries GRID EXPONENTIAL invests in
Stages GRID EXPONENTIAL invests in
Countries GRID EXPONENTIAL invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Federico Marque
|
|||
Matias Peire
|
|||
Eric Thomas
|
|||
Francisco Javier Salvatelli
|
|||
María Renner
|
Investment Focus
Industry
- Biotechnology 62 (61%)
- Life Science 13 (13%)
- Health Care 12 (12%)
- Manufacturing 6 (6%)
- AgTech 5 (5%)
Stage
- Pre-Seed 75 (74%)
- Seed 10 (10%)
- Series A 3 (3%)
- Funding Round 1 (1%)
- Convertible Note 1 (1%)
Country
- Argentina 34 (33%)
- United States 15 (15%)
- Mexico 6 (6%)
- Uruguay 6 (6%)
- Chile 4 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Federico Marque
General Partner
|
General Partner | Total investments: 7 | Find email | |
|
Matias Peire
Founder
|
Founder | Total investments: 3 | Find email | |
|
Eric Thomas
Head of Entrepreneur Relations
|
Head of Entrepreneur Relations | Total investments: 0 | Find email | |
|
Francisco Javier Salvatelli
Brazil Manager
|
Brazil Manager | Total investments: 2 | Find email | |
|
María Renner
Scientific Relations
|
Scientific Relations | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ALKEMIO
|
ALKEMIO is a developer of a bio-magnetic technology intended to transform electronic waste into quality battery-grade metals. | $2M / Seed / Mar 31, 2026 | |
OncoPrecision
|
We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity and Resistance Test, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access toPrecision Oncology and improve cancer patients' lives. | $4.5M / Seed / Nov 24, 2025 | |
Resistia
|
Developing next-gen antimicrobials against resistant biofilm-related infections. The global annual spending on human biofilm-related infections is around $400B, of which $35B is spent on antibiotics. Our solution platform based on new biological components discovery, allow us to offer the Biopharma industry the license of disruptive antimicrobialtherapeutic combinations (a B2B model). We attack bacteria with their "own medicine": using compounds of beneficial bacteria from healthy tissue's microbiota, synergistically combined with biopolymers and antibiotics. We have already conducted in vivo studies, proving our solution's safety and improving the efficacy of a commercial antibiotic from 30% to 85% with our co-formulation. We are bringing to market over 15 years of R&D experience in anti-biofilm solutions in high antimicrobial resistance environments, combined with a biopharma business strategy background. Our MVP is focused on Gram-positive infections (prosthetic joint and respiratory models). We strongly believe that: where antibiotics fail, our solution begins. | $250K / Pre-Seed / Oct 02, 2025 | |
Mavios
|
AI Digital Twin for Bioprocess | Pre-Seed / Jul 20, 2025 | |
BioClé
|
BioClé develops solutions for identifying, analyzing, and interpreting chemical, biological, radiological, and environmental hazards. The company provides software platforms that combine scientific models, data analysis tools, and scenario simulations to support informed decision-making in critical situations. Its systems allow users to detectpotential threats, evaluate their impact, and explore mitigation or response strategies. Its tools are designed to integrate into diverse operational workflows, offering configurable modules for different sectors and user requirements. By merging scientific expertise with practical applications, the company enables organizations to conduct accurate assessments, generate detailed reports, and enhance preparedness for complex hazard scenarios. | $250K / Pre-Seed / Jul 18, 2025 | |
Arakion
|
Bio insecticides from inspired by arachnid venom and enhanced with AI to equipo de crop protection industry with novel modes of action continuously. At Arakion we aim to outrun pests resistance with precision and efficacy. | $250K / Pre-Seed / Jul 08, 2025 | |
BioPlaster Research
|
BioPlaster Research seeks the development of science and technology for the care of the environment and the proliferation of nanotechnology. | $655K / May 06, 2025 | |
Puna Bio
|
Puna Bio develops biological inputs for agriculture that increase yields, reduce carbon emissions, and restore degraded soil. | $20.3M / Series A / Apr 22, 2025 | |
Aquit
|
Aquit develops preventive treatments for infections in fish that replace antibiotics, improve survival rates, and boost natural immunity. | $832K / Pre-Seed / Mar 19, 2025 | |
SphereBio
|
SphereBio develops biotech platforms that deliver molecules to cells, training them to generate specific responses to health issues. The company is now using platforms to offer pharmaceutical and veterinary companies a novel approach to potentiate vaccines and therapeutics tailored to specific diseases, such as cancer. It was founded in 2023. | Pre-Seed / Dec 12, 2024 | |
| See all 102 investments → | |||
Co-Investors
SOSV
14 deals together
SOSV SF & NY (Fka IndieBio)
8 deals together
GLOCAL LatAm
5 deals together
Creative Ventures
4 deals together
AIR Capital
3 deals together
At One Ventures
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does GRID EXPONENTIAL invest in?
GRID EXPONENTIAL invests primarily in Biotechnology, Life Science and Health Care startups, most often at Pre-Seed and Seed stage. Most of the 102 investments tracked by Shizune back companies in Argentina. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact GRID EXPONENTIAL?
Public channels for GRID EXPONENTIAL include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at GRID EXPONENTIAL?
The team at GRID EXPONENTIAL includes Federico Marque (General Partner), Matias Peire (Founder) and Eric Thomas (Head of Entrepreneur Relations). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
